| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Perfluorohexyloctane is a semifluorinated alkane that is used in the treatment of dry eye disease. It is an inert, slightly amphiphilic compound that contains six perfluorinated carbon atoms and eight hydrogenated carbon atoms. Due to its completely non-aqueous nature, it does not support microbial growth, which means that its drug products do not require any preservatives. The ophthalmic formulation of perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease, and it was approved by the FDA on May 18, 2023.
Perfluorohexyloctane is administered as an eye drop to alleviate symptoms of dry eye disease, increase tear film breakup time, and increase lipid layer thickness. It has low surface and interface tensions, which allow it to spread rapidly across the ocular surface, causing minimal visual disturbances due to its refractive index being similar to that of water. The exact mechanism of action is not fully understood, but it is believed to interact with the air-liquid interface of the tear film and form a monolayer, preventing the evaporation of the aqueous phase of the tears.
In terms of pharmacokinetics, perfluorohexyloctane penetrates meibomian glands, where it interacts with and dissolves the altered, viscous meibum in the glands. Studies have shown low systemic perfluorohexyloctane blood levels after topical ocular administration, with minimal systemic exposure.
){kind=link}